Teacher Retirement System of Texas Reduces Stake in Evolus, Inc. (NASDAQ:EOLS)

Teacher Retirement System of Texas trimmed its stake in Evolus, Inc. (NASDAQ:EOLSFree Report) by 14.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,398 shares of the company’s stock after selling 1,686 shares during the quarter. Teacher Retirement System of Texas’ holdings in Evolus were worth $109,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC boosted its stake in Evolus by 13.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 12,345 shares of the company’s stock valued at $113,000 after acquiring an additional 1,484 shares during the last quarter. Swiss National Bank boosted its holdings in Evolus by 1.8% in the 3rd quarter. Swiss National Bank now owns 93,800 shares of the company’s stock worth $857,000 after buying an additional 1,700 shares during the period. Kestra Advisory Services LLC boosted its holdings in Evolus by 18.5% in the 3rd quarter. Kestra Advisory Services LLC now owns 16,356 shares of the company’s stock worth $149,000 after buying an additional 2,550 shares during the period. Brandywine Global Investment Management LLC boosted its holdings in Evolus by 1.9% in the 3rd quarter. Brandywine Global Investment Management LLC now owns 158,200 shares of the company’s stock worth $1,446,000 after buying an additional 3,000 shares during the period. Finally, Barclays PLC boosted its holdings in Evolus by 24.5% in the 3rd quarter. Barclays PLC now owns 19,794 shares of the company’s stock worth $181,000 after buying an additional 3,889 shares during the period. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on EOLS shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Evolus in a report on Wednesday, May 8th. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Evolus in a report on Tuesday, May 21st.

Read Our Latest Report on Evolus

Insiders Place Their Bets

In other news, Director David N. Gill sold 3,643 shares of the firm’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $12.72, for a total transaction of $46,338.96. Following the sale, the director now owns 40,682 shares in the company, valued at approximately $517,475.04. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, Director David N. Gill sold 3,643 shares of the firm’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $12.72, for a total transaction of $46,338.96. Following the sale, the director now owns 40,682 shares in the company, valued at approximately $517,475.04. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Sandra Beaver sold 5,672 shares of the firm’s stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $13.92, for a total transaction of $78,954.24. Following the sale, the chief financial officer now owns 154,201 shares in the company, valued at approximately $2,146,477.92. The disclosure for this sale can be found here. Insiders have sold 61,628 shares of company stock worth $830,947 in the last three months. 6.10% of the stock is currently owned by corporate insiders.

Evolus Stock Performance

NASDAQ EOLS opened at $12.61 on Friday. Evolus, Inc. has a 1 year low of $7.07 and a 1 year high of $15.43. The company has a debt-to-equity ratio of 6.54, a current ratio of 3.21 and a quick ratio of 2.96. The stock has a market capitalization of $789.39 million, a PE ratio of -12.01 and a beta of 1.47. The company’s 50 day simple moving average is $12.85 and its two-hundred day simple moving average is $12.06.

Evolus (NASDAQ:EOLSGet Free Report) last posted its earnings results on Tuesday, May 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.05). The business had revenue of $59.33 million for the quarter, compared to analyst estimates of $58.78 million. Analysts predict that Evolus, Inc. will post -0.61 earnings per share for the current fiscal year.

Evolus Profile

(Free Report)

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Featured Articles

Want to see what other hedge funds are holding EOLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolus, Inc. (NASDAQ:EOLSFree Report).

Institutional Ownership by Quarter for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.